

## NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

### Melanoma

#### First Guideline Development Group (GDG) meeting

21<sup>st</sup> & 22<sup>nd</sup> May 2013

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

#### GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Fergus Macbeth (FM)	Julia Newton-Bishop (JNB)
Sara Stoneham (SS)	Barry Powell (BP)
Saskia Reeken (SR)	Gill Godsell (GG)
Laszlo Igali (LI)	Stephen Keohane (SK) (Day 1 only)
Martin Telfer (MT)	Christine Parkinson (CP)
Jonathan Smith (JSm)	Rachael Robinson (RR)
Julia Schofield (JSc)	Richard Jackson (RJ)
Simon Rodwell (SHR)	
NCC-C staff	
John Graham (JG)	Andrew Champion (AC)
Lianne Gwillim (LG)	Susan O'Connell (SOC)
Nathan Bromham (NB)	Victoria Kelly (VK)
Stephanie Arnold (SA)	Matthew Prettyjohns (MP) (Day 1 pm only)
NICE staff & Affiliated staff	
Barbara Meredith (BM)	Katie Perryman-Ford (KPF)
Veronique Poirier (VP)	
Apologies	
Charles Kelly (CK)	

#### REPORTS OF DISCUSSIONS AT THE MEETING

##### 1. Introductions

FM welcomed everyone to the 1<sup>st</sup> meeting of the Melanoma GDG and thanked the GDG members for volunteering for the group.

Each member of the group introduced themselves and gave a background to where they are from and what they do.

Apologies for absence were received from Charles Kelly.

##### 2. Declarations of Interest

FM gave a brief overview of the NICE conflict of interest policy to the group and noted that some GDG members had already declared interests in their applications. These were as follows:

- FM declared that he is chief investigator of a CRUK funded trial supported by Pfizer with free drug and unrestricted educational grant. This interest was categorised as non-personal pecuniary, non specific meaning that FM can declare and participate in discussions on all topics as lung cancer is not being covered by the guideline.

- GG declared that she has received reimbursement of travel and subsistence expenses from Almirall (manufacturers of topical treatments for pre-cancerous lesions) for attending a European Academy of Dermatology and Venerology meeting. This interest categorised as personal pecuniary, specific, meaning that GG can declare and participate in discussions on all topics as expenses were not beyond a reasonable amount.
- GG declared that she is vice chair of the Karen Clifford Skin Cancer Charity, and gives advice on the clinical aspects of skin cancer – not specific treatments. This interest was categorised as personal non-pecuniary and a chair persons action was taken meaning that a GG can declare and participate in discussions on all topics.
- SR declared that she has received an honorarium from Leo Pharmaceuticals for attending an advisory board on dermatology (their psoriasis treatments and new products – none relating to melanoma). This interest was categorised as personal pecuniary, non-specific meaning that SR can declare and participate in discussions on all topics as psoriasis treatments are not being covered by the guideline and other products are not relating to melanoma.
- SR declared that she has received an honorarium from the British Dermatology Nursing Group for giving a lecture on topical treatments for dermatology (specifically steroid creams). This interest was categorised as personal pecuniary, non-specific, meaning that SR can declare and participate in discussions on all topics as steroid creams are not being covered by the guideline.
- SR declared that she received reimbursement of travel expenses (from the organiser) for attending the British Association of Dermatology Nursing annual conference. This interest was categorised as personal pecuniary, non specific, meaning that SR can declare and participate in discussions on all topics as expenses are not beyond a reasonable amount.
- SR declared that she has received a fee from Janssen for giving a lecture to dermatology nurses on the recognition of skin cancer lesions (including melanoma) in patients with psoriasis and the practical skills for lymph node examination. This interest was categorised as personal pecuniary, specific, meaning that SR must declare and withdraw from discussions on all topics regarding the recognition of melanoma until May 2013. However, guideline development commenced in May 2013 so SR can participate in discussion on all topics.
- SR declared that she has received reimbursement of travel and subsistence expenses from the Danish Embassy in Copenhagen for attending a meeting on sun radiation and the effect on the environment. This interest was categorised as personal pecuniary, non specific, meaning that SR can declare and participate in discussions on all topics as sun radiation and the effect on the environment are not being covered by the guideline.
- SR declared that she a member of the CRUK Sun Smart Advisory Board, which looks at strategies for sun awareness and health promotion. This interest was categorised as personal non-pecuniary. A chair person's action was taken meaning that SR can declare and participate in discussions on all topics
- SR declared that she is a Member of the Melanoma Task Force, which is interested in improving the care of patients with melanoma. This interest was categorised as personal non-pecuniary. A chair person's action was taken meaning that SR can declare and participate in discussions on all topics.
- SR declared that she is a Nurse representative on the British Association of Dermatology skin cancer committee. This interest was categorised as

personal non-pecuniary. A chair person's action was taken meaning that SR can declare and participate in discussions on all topics.

- SR declared that she is a Nurse representative on Skin Cancer UK and provides advice on skin cancer issues. This interest was categorised as personal non-pecuniary. A chair person's action was taken meaning that SR can declare and participate in discussions on all topics.
- SS declared that she has received a fee from the Royal Marsden for giving a lecture on renal tumours in paediatric oncology as part of their MSc in Oncology. This interest was categorised as personal pecuniary non specific, meaning that SS can declare and participate in discussions on all topics as renal tumours are not being covered by the guideline.
- SS declared that she is principle investigator for the CNS 9204 trial (Neuropsychological, academic and functional outcomes in survivors of infant ependymoma (UKCCSG CNS 9204)). Funded by CRUK. SS was not involved in designing the trial protocol. This interest was categorised as non-personal pecuniary, non specific, meaning that SS can declare and participate in discussions on all topics as Neuropsychological, academic and functional outcomes in survivors of infant ependymoma is not being covered by the guideline.
- SS declared that she was principle investigator for the GC 2005 04 (GC-3) trial (Protocol for the treatment of Extracranial Germ Cell Tumours in children and adolescents). The trial closed in 2009, 1 patient is still in follow up. The trial was sponsored by University Hospitals of Leicester NHS Trust and funded by Children's Cancer and Leukaemia Group (CCLG). This interest was categorised as non-personal pecuniary, non specific, meaning that SS can declare and participate in discussions on all topics as protocol for the treatment of Extracranial Germ Cell Tumours in children and adolescents is not being covered by the guideline.
- SS declared that she is Co-investigator in the HERBY trial (study of high grade paediatric glioma, which is funded by Roche. This interest was categorised as non-personal pecuniary, non specific, meaning that SS can declare and participate in discussions on all topics as paediatric glioma is not being covered by the guideline.
- CP declared that she has received a fee from Boehringer Ingelheim for attending an advisory board and giving advice on trial design in December 2012 for their ovarian cancer drug BIBF1120. The fee was donated to charity. This interest was categorised as personal pecuniary, non specific, meaning that CP can declare and participate in discussions on all topics as ovarian cancer is not being covered by the guideline.
- CP declared that she received reimbursement of registration fees and accommodation from Boehringer Ingelheim for attending the International Gynaecological Cancer Society conference. This interest was categorised as personal pecuniary, non specific, meaning that CP can declare and participate in discussions on all topics as Gynaecological cancer is not being covered by the guideline.
- CP declared that she is co-investigator on the COMBI-V (phase III, randomised, double-blinded study evaluating the combination of MEK and BRAF Inhibitors vs dabrafenib in patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma). The trial is funded by GSK. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is co-investigator on the PACMEL (Paclitaxel with or without MEK inhibitor GSK1120212 for treatment of melanoma). Sponsored

by University of Oxford. The trial is funded by GSK. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.

- CP declared that she is co-investigator on the Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients with Advanced Malignant Melanoma). The study is sponsored and funded by Immunocore Ltd. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is co-investigator on the NICAM (Nilotinib for patients with advanced acral or mucosal melanoma). This trial is sponsored by Royal Marsden Foundation Trust and Institute of Cancer Research, and funded by CTAAC. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is Co-investigator on the IMAGE (observational study looking at quality of life in patients on ipilimumab). Funded by Bristol Myers Squibb. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is co-investigator on the SUAVE (randomised phase II study of Sunitinib versus Dacarbazine in the treatment of patients with metastatic uveal melanoma). Which is sponsored by Clatterbridge Centre for Oncology NHS Trust and funded by Pfizer Limited and CTAAC. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is co-investigator on the MelResist (translational study in melanoma – collection of blood and tissue samples). Which is funded by Cambridge University Hospitals NHS Foundation Trust. This interest was categorised as non-personal pecuniary, specific, meaning that CP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- CP declared that she is principle investigator on the PARAGON trial (Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms). Which is sponsored by NHS Greater Glasgow & Clyde and funded by CRUK. This interest was categorised as non-personal pecuniary, non specific, meaning that CP can declare and participate in discussion on all topics as aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms is not being covered by the guideline.
- MT declared that he has presented at the Yorkshire & Humber Regional Clinical Effectiveness Meeting on “Facial Skin Cancer Surgery: Patient Satisfaction”. No fee received. This interest was categorised as personal non-pecuniary and a chair persons action was taken meaning that MT can declare and participate in discussions on all topics.
- BP declared that he has received a fee from Roche for chairing an advisory board on BRAF inhibitors in malignant melanoma and has donated his fee to charity. This interest was categorised as personal pecuniary, specific, meaning that BP must declare and withdraw from discussions on all topics regarding the BRAF inhibitors until July 2013. However, discussion on BRAF inhibitors will not take place until July 2013.

- BP declared that Novartis have offered a fee to take part in a future advisory board on MEK inhibitors in melanoma. This offer has not yet accepted. If accepted this interest will be categorised as personal pecuniary specific meaning that BP must declare and withdraw from discussions on all topics regarding the MEK inhibitors until 12 months after date of advisory board. However, MEK inhibitors will not be investigated by the guideline.
- BP declared that he enrolls patients into the EORTC 18091 trial (A Phase I/II Open Label Multicenter Study of ONTAK® as Treatment for advanced melanoma (stage IIIc and stage IVM1a)). No fee is received for doing this and no involvement takes place past the enrolling of patients. This interest was categorised as personal non-pecuniary meaning that BP can declare and participate in discussion on all topics as no involvement in trial protocol.
- BP declared that he is principle investigator for the UK for the EORTC MINITUB study (looking at low volume disease in sentinel nodes). The study not yet started, and will be funded by individual trusts. This interest was categorised as personal non-pecuniary, specific meaning that BP can declare and participate in discussion on all topics as no supervisory responsibility on trials.
- BP declared that he is Chair of the Pathway Group for Skin Cancer for the London Cancer Alliance (working group on provision of skin cancer care in London). This interest was categorised as personal non-pecuniary and a chair person's action was taken meaning that BP can declare and participate in discussions on all topics.
- BP declared that he wrote an editorial for the surgery journal giving opinions on the management of malignant melanoma. This interest was categorised as personal non-pecuniary and a chair person's action was taken meaning that BP can declare and participate in discussions on all topics.
- LI declared that he has received a fee from St James' University Hospital, Leeds for speaking at a symposium on alopecia and immunohistochemistry in dermatopathology. This interest was categorised as personal pecuniary, non specific, meaning that LI can declare and participate in discussion on all topics as alopecia and immunohistochemistry is not being covered by the guideline.
- LI declared that he received reimbursement of travelling expenses from the Royal College of Pathologists for attending a council meeting. This interest was categorised as personal pecuniary and a chair person's action was taken meaning that LI can declare and participate in discussions on all topics.
- LI declared that he is involved in the EUR-GAST II study (investigating environmental factors, H. pylori infection and genetic susceptibility in gastric cancer risk in the European population), and he was the pathologist responsible for co-ordinating specimen collection and evaluation for the UK. No commercial funding was received. This interest was categorised as non-personal pecuniary, specific, meaning that LI can declare and participate in discussion on all topics as environmental factors, H. pylori infection and genetic susceptibility in gastric cancer risk in the European population is not being covered by the guideline.
- LI declared that he is involved in the EPIC study (european prospective investigation into cancer) and did selective pathology data collection and evaluation. No commercial funding was received. This interest was categorised as non-personal pecuniary meaning that LI can declare and participate in discussion on all topics as pathology data collection and evaluation is not being covered by the guideline.
- LI declared that he has supervised an MSc student investigating optimal fixation of metastatic melanoma for tissue banking. This interest was

categorised as non-personal pecuniary, non specific, meaning that LI can declare and participate as not funded by healthcare industry.

- LI declared that he is involved in a new prospective study looking at BRAF immunostaining in metastatic melanoma to stratify patients for future treatment. LI's role is to do the immunohistochemistry and report on the BRAF status. The research is funded by LI's employer. This interest was categorised as non-personal pecuniary, specific, meaning that LI can declare and participate as not funded by healthcare industry.
- LI declared that he ran a workshop on teledermatopathology as part of the American Society of Dermatopathology annual congress in October 2012. No fee was received for this activity. This interest was categorised as personal non-pecuniary meaning that LI can declare and participate in discussion on all topics as teledermatopathology is not being covered by the guideline.
- LI declared that he holds the post of editor of the Bulletin of the Royal College of Pathology. This interest was categorised as personal pecuniary and a chair person's action was taken meaning that LI can declare and participate in discussions on all topics.
- LI declared that he provides ad hoc advice to EZDerm on developing an integrated dermatology/electronic record system. No fee was received for this activity. This interest was categorised as personal pecuniary and a chair person's action was taken meaning that LI can declare and participate in discussions on all topics.
- LI declared that he is a member of the Interim Body to the Professional Records Standard Body, and provides IT advice on how their electronic records should be set up. This interest was categorised as personal pecuniary and a chair person's action was taken meaning that LI can declare and participate in discussions on all topics.
- RR declared that she has received a fee from the RCGP for taking part in a panel reviewing a musculoskeletal e-learning package. This interest was categorised as, personal pecuniary, non specific, meaning that RR can declare and participate in discussion on all topics as musculoskeletal e-learning packages are not being covered by the guideline.
- RR declared that she has received a fee from Galderma in for chairing an educational meeting of the Leeds Skin Club on the treatment of acne and red face. This interest was categorised as personal pecuniary, non specific, meaning that RR can declare and participate in discussion on all topics as the treatment of acne and red face is not being covered by the guideline.
- RR declared that she has received reimbursement of travel expenses from the Yorkshire Deanery for attending a meeting to talk about the new curriculum for GP registrars. This interest was categorised as personal pecuniary, non specific, meaning that RR can declare and participate in discussion on all topics as new curriculum for GP registrars is not being covered by the guideline.
- RR declared that her practice recruits patients into the 3C – cough complications co-hort study, organised by Oxford University. The practice receives an income for this activity which is shared amongst the GPs. This interest was categorised as non-personal pecuniary, non specific, meaning that RR can declare and participate in discussion on all topics as cough complications is not being covered by the guideline.
- RR declared that her practice recruits patients into the early arthritis study, organised by Leeds University. The practice receives an income for this activity which is shared amongst the GPs. This interest was categorised as non-personal pecuniary, non specific, meaning that RR can declare and

participate in discussion on all topics as transdermal patches for the treatment of chronic pain is not being covered by the guideline.

- RR declared that she is currently involved in reviewing an acne decision aid tool for the BMJ patient decision aid group. No fee is being received for involvement. This interest was categorised as personal non-pecuniary, meaning that RR can declare and participate in discussion on all topics as acne decision aid tools is not being covered by the guideline.
- JSc declared that she has received a fee from Basilea for advising on their product toctino (treatment for hand eczema) in the market place. This interest was categorised as personal pecuniary, non specific, meaning that JSc can declare and participate in discussion on all topics as hand eczema is not being covered by the guideline.
- JSc declared that she has received a fee and reimbursement of travel expenses from Leo Pharmaceuticals in January 2013 for giving a lecture on GPs with a special interest. This interest was categorised as personal pecuniary, meaning that JSc can declare and participate in discussion on all topics as GPs with a special interest is not being covered by the guideline
- JSc declared that she has received a fee and reimbursement of travel expenses from the British Dermatology Nursing Group in October 2012 for giving a lecture on dermoscopy and teledermatology in relation to skin cancer (including melanoma). This interest was categorised as personal pecuniary, specific, meaning that JSc can declare and participate in discussion on all topics as not funded by healthcare industry.
- JSc declared that she has received a fee and reimbursement of travel expenses from the Dowling Club (national dermatology educational society) to present at a meeting for dermatology trainees on delivering dermatology services. This interest was categorised as personal pecuniary, non specific meaning that JSc can declare and participate in discussion on all topics as delivering dermatology services is not being covered by the guideline.
- JSc declared that she has received a fee and reimbursement of travel expenses from the Primary Care Dermatology Society for presenting at a meeting on the management of pre-cancerous lesions in primary care. This interest was categorised as personal pecuniary, non specific meaning that JSc can declare and participate in discussion on all topics as management of pre-cancerous lesions in primary care is not being covered by the guideline
- JSc declared that she has received a fee and reimbursement of travel expenses from the Irish Primary Care Dermatology Society for presenting at a meeting on recognising skin lesions and paediatric dermatology problems. This interest was categorised as personal pecuniary, non specific, meaning that JSc can declare and participate in discussion on all topics as recognising skin lesions and paediatric dermatology problems is not being covered by the guideline
- JSc declared that during 2012, she acted as an advisory to Buckinghamshire NHS Trust on re-designing their dermatology services. This interest was categorised as personal pecuniary, non specific, meaning that JSc can declare and participate in discussion on all topics as re-designing dermatology services is not being covered by the guideline
- JSc declared that she is an external advisor to the All Party Parliamentary Group on Skin. This interest was categorised as personal on-pecuniary and a chair person's action was taken meaning that JSc can declare and participate in discussions on all topics.
- JSc declared that she is a trustee of the Psoriasis Association. This interest was categorised as personal on-pecuniary and a chair person's action was

taken meaning that JSc can declare and participate in discussions on all topics.

- SK declared that he has received a fee from Meda for attending an advisory board on their new treatment for actinic keratosis (Zyclara). This interest was categorised as personal pecuniary, non specific, meaning that SK can declare and participate in discussion on all topics as actinic keratosis is not being covered by the guideline.
- SK declared that he has received a fee from Almirall for giving a lecture on new advances in non melanoma skin cancer. This interest was categorised as personal pecuniary, non specific meaning that SK can declare and participate in discussion on all topics as non melanoma skin cancer is not being covered by the guideline.
- SK declared that he has received a fee from Leo Pharmaceuticals for attending an advisory board on their new treatment for actinic keratosis (Picato). This interest was categorised as personal pecuniary, non specific, meaning that SK can declare and participate in discussion on all topics as actinic keratosis is not being covered by the guideline.
- SK declared that he has received a fee from Roche for attending an advisory board on their treatment for advanced basal cell carcinoma (Everidge). This interest was categorised as personal pecuniary, non specific, meaning that SK can declare and participate in discussion on all topics as basal cell carcinoma is not being covered by the guideline.
- SK declared that he has received reimbursement of expenses (travel, accommodation, subsistence and conference fee) from Leo Pharmaceuticals for attending the American Academy of Dermatology conference. This interest was categorised as personal pecuniary, non specific, meaning that SK can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- SK declared that he is local principle investigator for a trial on Ingenol (treatment of facial and scalp actinic keratoses). The trial is funded by Leo Pharmaceuticals. SK is responsible for administrating the trial locally and was not involved in designing the trial protocol. This interest was categorised as non-personal pecuniary, non specific, meaning that SK can declare and participate in discussion on all topics as facial and scalp actinic keratosis is not being covered by the guideline.
- SK declared that he has chaired a meeting in on advanced melanoma management (content of the meeting was investigation and management and covered new therapeutic treatments including ipilumimab, vemfuranib, MEK inhibitors and DNA vaccines. The event was sponsored by Bristol Myers Squibb. SK did not receive a fee or organise the meeting. This interest was categorised as personal non-pecuniary, meaning that SK must declare and withdraw from discussions on all topics regarding ipilumimab, vemfuranib, MEK inhibitors and DNA vaccines inhibitors until September 2013.
- SK declared that he is a member of the National Cancer Intelligence Network Skin Reference Group – look at changing trends in skin cancer and how these impact on service provision. This interest was categorised as personal non-pecuniary, and a chair person's action was taken meaning that SK can declare and participate in discussions on all topics
- SK declared that he is chair of the British Association of Dermatologists Skin Cancer Committee – which looks at service provision and ensuring the quality of skin cancer care provided by dermatologists is equitable across the UK. This interest was categorised as personal non-pecuniary, and a chair person's action was taken meaning that SK can declare and participate in discussions on all topics



- SK declared that he is chair of the Skin Cancer Site Specific Group of the Central South Coast Cancer Network – which looks at local service provision and co-ordinate regional audits etc. This interest was categorised as personal non-pecuniary, and a chair person's action was taken meaning that SK can declare and participate in discussions on all topics

No new interests were declared at the meeting. The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

### 3. Discussions

The GDG were given presentations on:

- Introduction to NICE
- An overview of the guideline development process
- Time table for guideline development
- Patient & carer involvement in guideline development
- Needs assessment data for melanoma
- Guideline methodology development
- Health Economics in NICE guidelines

The GDG discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO question for topics F, G, H, I, J1, J2, E, K1, M1, M2, N & B

The GDG discussed topics which were potential priorities for economic investigation.

### 4. Close of meeting

FM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Tuesday 23<sup>rd</sup> July 2013**, starting at 10.30am in the **Temple of Health & Peace, Kind Edward VII Avenue, Cardiff CF10 3AP** and closed the meeting.